In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

Boston Scientific Corporation BSX shares are down on Monday as the company faces pressure following a significant clinical ...

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration is warning patients and doctors about possible issues seen with Boston Scientific heart ...

Boston Scientific (NYSE:BSX) shares fell 9% after the company’s CHAMPION-AF trial results for its Watchman heart implant failed to meet investor expectations, d ...

Today, March 30, 2026, investors send Boston Scientific shares lower as they dig deeper into the company's latest trial ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — U.S. health regulators are ...

WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and ...